2R3 Stock Overview
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Reata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$161.00 |
| 52 Week High | US$161.00 |
| 52 Week Low | US$22.60 |
| Beta | 1.42 |
| 1 Month Change | 3.21% |
| 3 Month Change | 81.92% |
| 1 Year Change | 582.20% |
| 3 Year Change | 103.80% |
| 5 Year Change | 146.74% |
| Change since IPO | 730.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2R3 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.6% | -1.0% | -1.7% |
| 1Y | 582.2% | -30.1% | 1.4% |
Return vs Industry: 2R3 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 2R3 exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 2R3 volatility | |
|---|---|
| 2R3 Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2R3's share price has been volatile over the past 3 months.
Volatility Over Time: 2R3's weekly volatility has decreased from 27% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 322 | J. Huff | www.reatapharma.com |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease.
Reata Pharmaceuticals, Inc. Fundamentals Summary
| 2R3 fundamental statistics | |
|---|---|
| Market cap | €6.21b |
| Earnings (TTM) | -€82.91m |
| Revenue (TTM) | €22.22m |
279.7x
P/S Ratio-74.9x
P/E RatioIs 2R3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2R3 income statement (TTM) | |
|---|---|
| Revenue | US$23.48m |
| Cost of Revenue | US$204.15m |
| Gross Profit | -US$180.67m |
| Other Expenses | -US$93.05m |
| Earnings | -US$87.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | -769.46% |
| Net Profit Margin | -373.18% |
| Debt/Equity Ratio | 83.8% |
How did 2R3 perform over the long term?
See historical performance and comparison